MASM7 is an activator of mitofusins that promotes mitochondrial fusion through mitofusins. It increases mitochondrial AR in MEFs in a concentration-dependent manner, with an EC50 value of 75 nM. MASM7 also directly binds to the HR2 domain of MFN2 with a dissociation constant (Kd) of 1.1 μM, effectively activating MFN2 or MFN to induce fusion.

Propranolol is a non-selective antagonist of β-adrenergic receptors (βAR), with Ki values of 1.8 nM for β1AR and 0.8 nM for β2AR, effectively lowering cAMP levels and activating the MAPK pathway downstream of βARs. It is an effective treatment for infantile hemangiomas (IHs), where it induces antiproliferative and antisurvival effects on hemangioma stem cells (HemSCs).

MASM7 is an activator of mitofusins that promotes mitochondrial fusion through mitofusins. It increases mitochondrial AR in MEFs in a concentration-dependent manner, with an EC50 value of 75 nM. MASM7 also directly binds to the HR2 domain of MFN2 with a dissociation constant (Kd) of 1.1 μM, effectively activating MFN2 or MFN to induce fusion.

Z-VAD is a competitive, irreversible pan-caspase inhibitor with broad specificity and weakly inhibits caspase-2. It induces autophagy and necrosis in irradiated breast and lung cancer models.

MASM7 is an activator of mitofusins that promotes mitochondrial fusion through mitofusins. It increases mitochondrial AR in MEFs in a concentration-dependent manner, with an EC50 value of 75 nM. MASM7 also directly binds to the HR2 domain of MFN2 with a dissociation constant (Kd) of 1.1 μM, effectively activating MFN2 or MFN to induce fusion.

Z-VAD is a competitive, irreversible pan-caspase inhibitor with broad specificity and weakly inhibits caspase-2. It induces autophagy and necrosis in irradiated breast and lung cancer models.

Z-VAD is a competitive, irreversible pan-caspase inhibitor with broad specificity and weakly inhibits caspase-2. It induces autophagy and necrosis in irradiated breast and lung cancer models.

Z-VAD is a competitive, irreversible pan-caspase inhibitor with broad specificity and weakly inhibits caspase-2. It induces autophagy and necrosis in irradiated breast and lung cancer models.

Lenumlostat (PAT-1251, GB2064) is a potent, selective, and orally available inhibitor of lysyl oxidase-like 2 (LOXL2). It exhibits greater selectivity for LOXL2 over other family members, with IC50 of 0.71 μM for hLOXL2 and 1.17 μM for hLOXL3. It also possesses anti-fibrotic properties.

Lenumlostat (PAT-1251, GB2064) is a potent, selective, and orally available inhibitor of lysyl oxidase-like 2 (LOXL2). It exhibits greater selectivity for LOXL2 over other family members, with IC50 of 0.71 μM for hLOXL2 and 1.17 μM for hLOXL3. It also possesses anti-fibrotic properties.